Generic Drug Labeling Survey Provides New Fodder In Battle Over Rule
This article was originally published in The Pink Sheet Daily
GPhA says most physicians, physician assistants and pharmacists surveyed believe the proposed rule will lead to confusion and affect the prescribing of generic drugs.
You may also be interested in...
FDA proposed rule would allow ANDA holders to unilaterally make label changes prior to FDA’s approval; NDA and other ANDA holders would have 30 days to revise their labels once FDA approves the change.
Court finds US FDA did not impede Catalyst orphan exclusivity for Firdapse as it approved different indication for competing product. Biogen loses 10-year patent battle against competing multiple sclerosis drug makers.
Pink Sheet reporter and editors examine the struggle over the FDA’s reputation, whether a coronavirus vaccine could be made available without sponsor cooperation, and the late Supreme Court Justice Ruth Bader Ginsburg’s legacy for pharma.